As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. ObesityWeek, which started in 2013, attracted ...

It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field's next frontier: staving off the losses ...

Novo Nordisk disclosed several key updates from its cardiometabolic and hematology pipelines Wednesday as the drugmaker ...

Response Pharmaceuticals believes its experimental drug can lessen the persistent weight gain associated with antipsychotics.

Troubled mental health startup Cerebral has agreed to pay nearly $3.7 million in connection with its efforts to encourage unauthorized prescriptions of ADHD medications and other ...

Catalent reported a slight revenue upswing during its latest quarterly results, which CEO Alessandro Maselli attributed to ...

Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The ...

Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with ...

Zealand is po­si­tion­ing the drug as a po­ten­tial stand­alone re­place­ment for GLP-1s or as the first med­i­cine that ...

Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...

Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

Vertex said it made $2 million in revenue from the first patient who received its sickle cell therapy Casgevy. The commercial launches of Casgevy and bluebird bio’s Lyfgenia have been ...